Venetoclax API Suppliers & Bulk Manufacturers

Available Forms: API (drug substance)

Available Strengths: Supplied to an in-house or pharmacopoeial specification

Reference Brands: Venclexta, Venclyxto

Category: Active Pharmaceutical Ingredient

Venetoclax is an oral BCL-2 inhibitor used to treat certain leukaemias. It is sourced by formulation manufacturers, CDMOs and R&D teams preparing generic development and filing batches.

Product Description:

Venetoclax is a selective inhibitor of BCL-2, a protein that helps cancer cells avoid programmed cell death; blocking it allows leukaemia cells to undergo apoptosis. It is approved for adults with chronic lymphocytic leukaemia or small lymphocytic lymphoma, and, with azacitidine, decitabine or low-dose cytarabine, for newly diagnosed acute myeloid leukaemia in adults aged 75 or over or with conditions that rule out intensive chemotherapy (reference brands: Venclexta, Venclyxto).

Specification at a glance

Regulatory files and timing

The FDA list of Drug Master Files (third quarter 2026) shows 8 active Type II API DMFs for this molecule. Few filings usually means few qualified sources, so early contact with suppliers pays off. For Europe, ask whether the supplier holds a CEP or an EU ASMF and, for imports into the EU, a written confirmation.

Generic or biosimilar entry. United States: Patent expiry; entry not confirmed (Jun 2031 (compound patent)). European Union: No confirmed date.

Handling and quality points

Venetoclax is a large, poorly soluble molecule, so solid form, particle size and residual solvents all matter to the formulator working on dissolution. It carries a nitroaromatic group and a piperazine ring, so ask for a mutagenic impurity assessment under ICH M7 and a nitrosamine risk assessment. It is a potent anticancer agent and is usually handled under containment, with cleaning validation expected at shared sites.

Send an API enquiry All specialty APIs

Brand names are trademarks of their respective owners and identify the reference medicine only. Information is general and was checked in October 2026; confirm specifications and filings with the supplier before purchase.